Keratoacanthoma
☆ AI Dermatology — Free Service
Na nsonaazụ Stiftung Warentest nke 2022 sitere na Germany, afọ ojuju ndị ahịa na ModelDerm dị ntakịrị ntakịrị karịa na nyocha telemedicine akwụ ụgwọ.
Na nsonaazụ Stiftung Warentest nke 2022 sitere na Germany, afọ ojuju ndị ahịa na ModelDerm dị ntakịrị ntakịrị karịa na nyocha telemedicine akwụ ụgwọ.
Ụdị keratoacanthoma
relevance score : -100.0%
ReferencesKeratoacanthoma (KA) bụ akpụkpọ-azụ a na-ahụkarị maka uto ngwa ngwa yana ikike ịlaghachi azụ n’onwe ya. Ọ na-emekarị n’ụlọ ndị agadi nwoke nwere akpụkpọ ahụ mara mma ma nwere akụkọ ihe mere eme nke mmebi anyanwụ. Ọ bụ ezie na mwepụ site na iji excision ma ọ bụ excision micrographic Mohs bụ ọgwụgwọ a na-emebu, enwere nhọrọ ọgwụgwọ ndị ọzọ dị.
Keratoacanthoma (KA) is a common cutaneous tumor characterized by rapid growth and possible spontaneous regression. It most commonly affects older, fair-skinned males with significantly sun damaged skin. Although surgical removal with excision or Mohs micrographic surgery remains the standard of therapy, there are many alternative therapeutic modalities that can be utilized.
Keratoacanthoma (KA) is a common cutaneous tumor characterized by rapid growth and possible spontaneous regression. It most commonly affects older, fair-skinned males with significantly sun damaged skin. Although surgical removal with excision or Mohs micrographic surgery remains the standard of therapy, there are many alternative therapeutic modalities that can be utilized.
Keratoacanthoma (KA) bụ ọrịa akpụkpọ anụ dị obere nke na-amalite n’ụfọdụ glandụ na akpụkpọ ahụ ma yie squamous cell carcinoma (SCC) n'okpuru microscope. Enwere arụrụmụka na-aga n'ihu gbasara ma a ga-ekewa KA dị ka ụdị SCC na-akpata.
Keratoacanthoma (KA) is a comparatively common low-grade tumor that initiates in the pilo-sebaceous glands and pathologically mimics squamous cell carcinoma (SCC). Essentially, strong debates confirm classifying keratoacanthoma as a variant of invasive SCC. The clinical behavior of KA is hardly predictable and the differential diagnosis of keratoacanthoma and other conditions with keratoacanthoma-like pseudocarcinomatous epithelial hyperplasia is challenging, both clinically and histopathologically.
Keratoacanthoma (KA) is a comparatively common low-grade tumor that initiates in the pilo-sebaceous glands and pathologically mimics squamous cell carcinoma (SCC). Essentially, strong debates confirm classifying keratoacanthoma as a variant of invasive SCC. The clinical behavior of KA is hardly predictable and the differential diagnosis of keratoacanthoma and other conditions with keratoacanthoma-like pseudocarcinomatous epithelial hyperplasia is challenging, both clinically and histopathologically.
Cutaneous squamous cell carcinoma (cSCC) bụ ụdị ọrịa kansa nke abụọ na-adịkarị n'etiti ndị agadi. A na-ejikarị ịwa ahụ agwọ cSCC, ma maka ụfọdụ ndị ọrịa na-enweghị ike ịwa ahụ ma ọ bụ họrọ ịghara ya, nhọrọ ndị ọzọ dị ka ọgwụgwọ intralesional nwere ike ịtụle. Ejila ọgwụgwọ intralesional ọdịnala (methotrexate ma ọ bụ 5-fluorouracil), mana enwere nyocha na-aga n'ihu na ụzọ ọhụrụ dị ka intralesional immunotherapy na oncolytic virotherapy. N'ebe a, anyị ga-eleba anya n'ọgwụgwọ intralesional dị iche iche maka cSCC, site na usoro kpochapụvo ruo na atụmatụ dị egwu.
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent cancer in humans, and it is especially common in fragile, elderly people. Surgery is the standard treatment for cSCC but intralesional treatments can be an alternative in those patients who are either not candidates or refuse to undergo surgery. Classic intralesional treatments, including methotrexate or 5-fluorouracil, have been implemented, but there is now a landscape of active research to incorporate intralesional immunotherapy and oncolytic virotherapy into the scene, which might change the way we deal with cSCC in the future. In this review, we focus on intralesional treatments for cSCC (including keratoacanthoma), from classic to very novel strategies.
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent cancer in humans, and it is especially common in fragile, elderly people. Surgery is the standard treatment for cSCC but intralesional treatments can be an alternative in those patients who are either not candidates or refuse to undergo surgery. Classic intralesional treatments, including methotrexate or 5-fluorouracil, have been implemented, but there is now a landscape of active research to incorporate intralesional immunotherapy and oncolytic virotherapy into the scene, which might change the way we deal with cSCC in the future. In this review, we focus on intralesional treatments for cSCC (including keratoacanthoma), from classic to very novel strategies.
N'okpuru mikroskopu, keratoacanthoma yiri carcinoma squamous cell nke ukwuu. Ọ bụ ezie na ụfọdụ ndị ọkachamara na-ahụ maka ọrịa na-ekewa keratoacanthoma dị ka ihe dị iche, ọ bụghị ihe ọjọọ, ihe dị ka 6 % nke keratoacanthoma a chọpụtara n'ụlọ ọgwụ site n'ịchọpụta histological na-eme ka ọ bụrụ cancer squamous cell.
○ Diagnosis na ọgwụgwọ
#Dermoscopy
#Skin biopsy